LABELS · dac3f1a8-101b-46cf-86b7-f289bc764813

AVSOLA

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2026-07-22
Captured: 2026-09-09T23:38:02.384588+00:00
Current indication reconciliation: Not reconciled

Boxed warning in this label

WARNING: SERIOUS INFECTIONS and MALIGNANCY WARNING: SERIOUS INFECTIONS and MALIGNANCY See full prescribing information for complete boxed warning. Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis) and infections due to other opportunistic pathogens. ( 5.1 ) Discontinue AVSOLA if a patient develops a serious infection. Perform test for latent TB; if positive, start treatment for TB prior to starting AVSOLA. Monitor all patients for active TB during treatment, even if initial latent TB test is negative. ( 5.1 ) Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including infliximab products. ( 5.2 ) Postmarketing cases of fatal hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with TNF blockers including infliximab products. Almost all had received azathioprine or 6-mercaptopurine concomitantly with a TNF blocker at or prior to diagnosis. The majority of cases were reported in patients with Crohn's disease or ulcerative colitis, most of whom were adolescent or young adult males. ( 5.2 ) SERIOUS INFECTIONS Patients treated with infliximab products are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions (5.1) and Adverse Reactions (6.1) ] . Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. AVSOLA should be discontinued if a patient develops a serious infection or sepsis. Reported infections include: Active tuberculosis, including reactivation of latent tuberculosis. Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent tuberculosis before AVSOLA use and during therapy. Treatment for latent infection should be initiated prior to AVSOLA use. Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness. Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria. The risks and benefits of treatment with AVSOLA should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with AVSOLA, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. MALIGNANCY Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including infliximab products [see Warnings and Precautions (5.2) ] . Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers including infliximab products. These cases have had a very aggressive disease course and have been fatal. Almost all patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with a TNF blocker at or prior to diagnosis. The majority of reported cases have occurred in patients with Crohn's disease or ulcerative colitis and most were in adolescent and young adult males.

Indications and usage: exact source text

1 INDICATIONS AND USAGE AVSOLA is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease : reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.1 ) reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease. ( 1.1 ) Pediatric Crohn's Disease : reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.2 ) Ulcerative Colitis : reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.3 ) Pediatric Ulcerative Colitis : reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.4 ) Rheumatoid Arthritis in combination with methotrexate : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active disease. ( 1.5 ) Ankylosing Spondylitis : reducing signs and symptoms in adult patients with active disease. ( 1.6 ) Psoriatic Arthritis : reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients. ( 1.7 ) Plaque Psoriasis : treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. ( 1.8 ) 1.1 Crohn's Disease AVSOLA is indicated for: reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease (CD) who have had an inadequate response to conventional therapy. reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing CD. 1.2 Pediatric Crohn's Disease AVSOLA is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active CD who have had an inadequate response to conventional therapy. 1.3 Ulcerative Colitis AVSOLA is indicated for reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to conventional therapy. 1.4 Pediatric Ulcerative Colitis AVSOLA is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active UC who have had an inadequate response to conventional therapy. 1.5 Rheumatoid Arthritis AVSOLA, in combination with methotrexate, is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis (RA). 1.6 Ankylosing Spondylitis AVSOLA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis (AS). 1.7 Psoriatic Arthritis AVSOLA is indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients with psoriatic arthritis (PsA). 1.8 Plaque Psoriasis AVSOLA is indicated for the treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis (Ps) who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. AVSOLA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Boxed Warning and Warnings and Precautions (5) ] .

Full extracted label fields

application numbers

BLA761086

boxed warning exact

WARNING: SERIOUS INFECTIONS and MALIGNANCY WARNING: SERIOUS INFECTIONS and MALIGNANCY See full prescribing information for complete boxed warning. Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis) and infections due to other opportunistic pathogens. ( 5.1 ) Discontinue AVSOLA if a patient develops a serious infection. Perform test for latent TB; if positive, start treatment for TB prior to starting AVSOLA. Monitor all patients for active TB during treatment, even if initial latent TB test is negative. ( 5.1 ) Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including infliximab products. ( 5.2 ) Postmarketing cases of fatal hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with TNF blockers including infliximab products. Almost all had received azathioprine or 6-mercaptopurine concomitantly with a TNF blocker at or prior to diagnosis. The majority of cases were reported in patients with Crohn's disease or ulcerative colitis, most of whom were adolescent or young adult males. ( 5.2 ) SERIOUS INFECTIONS Patients treated with infliximab products are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions (5.1) and Adverse Reactions (6.1) ] . Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. AVSOLA should be discontinued if a patient develops a serious infection or sepsis. Reported infections include: Active tuberculosis, including reactivation of latent tuberculosis. Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent tuberculosis before AVSOLA use and during therapy. Treatment for latent infection should be initiated prior to AVSOLA use. Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness. Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria. The risks and benefits of treatment with AVSOLA should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with AVSOLA, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. MALIGNANCY Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including infliximab products [see Warnings and Precautions (5.2) ] . Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers including infliximab products. These cases have had a very aggressive disease course and have been fatal. Almost all patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with a TNF blocker at or prior to diagnosis. The majority of reported cases have occurred in patients with Crohn's disease or ulcerative colitis and most were in adolescent and young adult males.

brand names

AVSOLA

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de34bcb7-b524-45c8-9181-61c6f48d540e

generic names

INFLIXIMAB-AXXQ

dac3f1a8-101b-46cf-86b7-f289bc764813

indications and usage exact

1 INDICATIONS AND USAGE AVSOLA is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease : reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.1 ) reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease. ( 1.1 ) Pediatric Crohn's Disease : reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.2 ) Ulcerative Colitis : reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.3 ) Pediatric Ulcerative Colitis : reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.4 ) Rheumatoid Arthritis in combination with methotrexate : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active disease. ( 1.5 ) Ankylosing Spondylitis : reducing signs and symptoms in adult patients with active disease. ( 1.6 ) Psoriatic Arthritis : reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients. ( 1.7 ) Plaque Psoriasis : treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. ( 1.8 ) 1.1 Crohn's Disease AVSOLA is indicated for: reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease (CD) who have had an inadequate response to conventional therapy. reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing CD. 1.2 Pediatric Crohn's Disease AVSOLA is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active CD who have had an inadequate response to conventional therapy. 1.3 Ulcerative Colitis AVSOLA is indicated for reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to conventional therapy. 1.4 Pediatric Ulcerative Colitis AVSOLA is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active UC who have had an inadequate response to conventional therapy. 1.5 Rheumatoid Arthritis AVSOLA, in combination with methotrexate, is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis (RA). 1.6 Ankylosing Spondylitis AVSOLA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis (AS). 1.7 Psoriatic Arthritis AVSOLA is indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients with psoriatic arthritis (PsA). 1.8 Plaque Psoriasis AVSOLA is indicated for the treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis (Ps) who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. AVSOLA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Boxed Warning and Warnings and Precautions (5) ] .

indications and usage tables exact

is original packager

true

manufacturer names

Amgen, Inc

matched search terms

tumor

package ndcs

55513-670-01
55513-670-21

product ndcs

55513-670

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

INTRAVENOUS

rxcuis

2266525
2266530

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00700.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

BLA761086

brand names

AVSOLA

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 502
end exclusive: true
exact text: 1 INDICATIONS AND USAGE AVSOLA is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease : reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.1 ) reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease. ( 1.1 ) Pediatric Crohn's Disease : reduc
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 0

current approval status

not_reconciled

duplicate text group

dup-b6ae558774b63bf23160

extraction review status

automated_candidate_pending_source_review

generic names

INFLIXIMAB-AXXQ

ind-span-fea93223a38476290fff

label id

dac3f1a8-101b-46cf-86b7-f289bc764813

positive predicate support span

end: 81
end exclusive: true
exact text: is a tumor necrosis factor (TNF) blocker indicated
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 31

qualifier mentions

context exact
symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an
kind
age
polarity
not_inferred
span
end
198
end exclusive
true
exact text
adult patients
label id
dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start
184

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 302
end exclusive: true
exact text: 1 INDICATIONS AND USAGE AVSOLA is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease : reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy.
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%22dac3f1a8-101b-46cf-86b7-f289bc764813%22

spl effective date

2026-07-22

spl set id

de34bcb7-b524-45c8-9181-61c6f48d540e

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 2 · positive indication candidate

application numbers

BLA761086

brand names

AVSOLA

classification reasons

inherited_predicate_from_same_label_section_requires_review
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 660
end exclusive: true
exact text: : reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.1 ) reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease. ( 1.1 ) Pediatric Crohn's Disease : reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disea
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 103

current approval status

not_reconciled

duplicate text group

dup-8f6ab7cb944c1eadb04b

extraction review status

automated_candidate_pending_source_review

generic names

INFLIXIMAB-AXXQ

ind-span-ab2fed10c513aa0adc20

label id

dac3f1a8-101b-46cf-86b7-f289bc764813

positive predicate support span

end: 81
end exclusive: true
exact text: is a tumor necrosis factor (TNF) blocker indicated
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 31

qualifier mentions

context exact
nd rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease.
kind
age
polarity
not_inferred
span
end
434
end exclusive
true
exact text
adult patients
label id
dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start
420

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 460
end exclusive: true
exact text: ( 1.1 ) reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease.
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 303

source url

https://api.fda.gov/drug/label.json?search=id%3A%22dac3f1a8-101b-46cf-86b7-f289bc764813%22

spl effective date

2026-07-22

spl set id

de34bcb7-b524-45c8-9181-61c6f48d540e

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 3 · unclassified context

application numbers

BLA761086

brand names

AVSOLA

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 668
end exclusive: true
exact text: dequate response to conventional therapy. ( 1.1 ) reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease. ( 1.1 ) Pediatric Crohn's Disease : reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who h
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 261

current approval status

not_reconciled

duplicate text group

dup-939b0079c448a341f1e3

extraction review status

automated_candidate_pending_source_review

generic names

INFLIXIMAB-AXXQ

ind-span-f41e0e81a18524ed6048

label id

dac3f1a8-101b-46cf-86b7-f289bc764813

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 468
end exclusive: true
exact text: ( 1.1 )
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 461

source url

https://api.fda.gov/drug/label.json?search=id%3A%22dac3f1a8-101b-46cf-86b7-f289bc764813%22

spl effective date

2026-07-22

spl set id

de34bcb7-b524-45c8-9181-61c6f48d540e

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · positive indication candidate

application numbers

BLA761086

brand names

AVSOLA

classification reasons

inherited_predicate_from_same_label_section_requires_review
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 923
end exclusive: true
exact text: response to conventional therapy. ( 1.1 ) reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease. ( 1.1 ) Pediatric Crohn's Disease : reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.2 ) Ulcerative Colitis : reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to seve
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 269

current approval status

not_reconciled

duplicate text group

dup-ff9f78530ce59012e092

extraction review status

automated_candidate_pending_source_review

generic names

INFLIXIMAB-AXXQ

ind-span-d244e0650bb1eab11f62

label id

dac3f1a8-101b-46cf-86b7-f289bc764813

positive predicate support span

end: 81
end exclusive: true
exact text: is a tumor necrosis factor (TNF) blocker indicated
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 31

qualifier mentions

context exact
Pediatric Crohn's Disease : reducing signs and symptoms and inducing
kind
age
polarity
not_inferred
span
end
478
end exclusive
true
exact text
Pediatric
label id
dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start
469
context exact
symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active
kind
age
polarity
not_inferred
span
end
594
end exclusive
true
exact text
pediatric patients
label id
dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start
576
context exact
ng and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who ha
kind
age
polarity
not_inferred
span
end
609
end exclusive
true
exact text
6 years of age
label id
dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start
595

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 723
end exclusive: true
exact text: Pediatric Crohn's Disease : reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy.
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 469

source url

https://api.fda.gov/drug/label.json?search=id%3A%22dac3f1a8-101b-46cf-86b7-f289bc764813%22

spl effective date

2026-07-22

spl set id

de34bcb7-b524-45c8-9181-61c6f48d540e

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 5 · positive indication candidate

application numbers

BLA761086

brand names

AVSOLA

classification reasons

inherited_predicate_from_same_label_section_requires_review
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1203
end exclusive: true
exact text: and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.2 ) Ulcerative Colitis : reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.3 ) Pediatric Ulcerative Colitis : reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active di
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 524

current approval status

not_reconciled

duplicate text group

dup-1c6de9acc2cede52c1d2

extraction review status

automated_candidate_pending_source_review

generic names

INFLIXIMAB-AXXQ

ind-span-31d838872f38b9d3d107

label id

dac3f1a8-101b-46cf-86b7-f289bc764813

positive predicate support span

end: 81
end exclusive: true
exact text: is a tumor necrosis factor (TNF) blocker indicated
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 31

qualifier mentions

context exact
and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an
kind
age
polarity
not_inferred
span
end
899
end exclusive
true
exact text
adult patients
label id
dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start
885

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1003
end exclusive: true
exact text: ( 1.2 ) Ulcerative Colitis : reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy.
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 724

source url

https://api.fda.gov/drug/label.json?search=id%3A%22dac3f1a8-101b-46cf-86b7-f289bc764813%22

spl effective date

2026-07-22

spl set id

de34bcb7-b524-45c8-9181-61c6f48d540e

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 6 · unclassified context

application numbers

BLA761086

brand names

AVSOLA

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1211
end exclusive: true
exact text: ng clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.3 ) Pediatric Ulcerative Colitis : reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease wh
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 804

current approval status

not_reconciled

duplicate text group

dup-f9a534e48a4277eb65ce

extraction review status

automated_candidate_pending_source_review

generic names

INFLIXIMAB-AXXQ

ind-span-391fb8c6cba15e04c20c

label id

dac3f1a8-101b-46cf-86b7-f289bc764813

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1011
end exclusive: true
exact text: ( 1.3 )
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 1004

source url

https://api.fda.gov/drug/label.json?search=id%3A%22dac3f1a8-101b-46cf-86b7-f289bc764813%22

spl effective date

2026-07-22

spl set id

de34bcb7-b524-45c8-9181-61c6f48d540e

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 7 · unclassified context

application numbers

BLA761086

brand names

AVSOLA

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1469
end exclusive: true
exact text: cal remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.3 ) Pediatric Ulcerative Colitis : reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.4 ) Rheumatoid Arthritis in combination with methotrexate : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with mo
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 812

current approval status

not_reconciled

duplicate text group

dup-c98d0d66c353734629da

extraction review status

automated_candidate_pending_source_review

generic names

INFLIXIMAB-AXXQ

ind-span-6cf6f030ef0e38d7c4fa

label id

dac3f1a8-101b-46cf-86b7-f289bc764813

positive predicate support span

Source null

qualifier mentions

context exact
Pediatric Ulcerative Colitis : reducing signs and symptoms and induci
kind
age
polarity
not_inferred
span
end
1021
end exclusive
true
exact text
Pediatric
label id
dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start
1012
context exact
symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active
kind
age
polarity
not_inferred
span
end
1140
end exclusive
true
exact text
pediatric patients
label id
dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start
1122
context exact
ng and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who ha
kind
age
polarity
not_inferred
span
end
1155
end exclusive
true
exact text
6 years of age
label id
dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start
1141

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1269
end exclusive: true
exact text: Pediatric Ulcerative Colitis : reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy.
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 1012

source url

https://api.fda.gov/drug/label.json?search=id%3A%22dac3f1a8-101b-46cf-86b7-f289bc764813%22

spl effective date

2026-07-22

spl set id

de34bcb7-b524-45c8-9181-61c6f48d540e

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · unclassified context

application numbers

BLA761086

brand names

AVSOLA

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1705
end exclusive: true
exact text: and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.4 ) Rheumatoid Arthritis in combination with methotrexate : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active disease. ( 1.5 ) Ankylosing Spondylitis : reducing signs and symptoms in adult patients with active disease. ( 1.6 ) Psoriatic Arthritis : reducing signs and symptoms of active arthritis, inhibiting the progr
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 1070

current approval status

not_reconciled

duplicate text group

dup-0c13113a937e89285370

extraction review status

automated_candidate_pending_source_review

generic names

INFLIXIMAB-AXXQ

ind-span-84a12df6a769db587dc1

label id

dac3f1a8-101b-46cf-86b7-f289bc764813

positive predicate support span

Source null

qualifier mentions

context exact
on of structural damage, and improving physical function in adult patients with moderately to severely active disease.
kind
age
polarity
not_inferred
span
end
1461
end exclusive
true
exact text
adult patients
label id
dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start
1447
context exact
( 1.4 ) Rheumatoid Arthritis in combination with methotrexate : reducing signs and symptoms, inhibiting the progression of structural damage, and impro
kind
biomarker
polarity
not_inferred
span
end
1361
end exclusive
true
exact text
methotrexate : reducing signs and symptoms
label id
dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start
1319
context exact
( 1.4 ) Rheumatoid Arthritis in combination with methotrexate : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active disease.
kind
regimen
polarity
not_inferred
span
end
1478
end exclusive
true
exact text
in combination with methotrexate : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately
label id
dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start
1299

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1505
end exclusive: true
exact text: ( 1.4 ) Rheumatoid Arthritis in combination with methotrexate : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active disease.
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 1270

source url

https://api.fda.gov/drug/label.json?search=id%3A%22dac3f1a8-101b-46cf-86b7-f289bc764813%22

spl effective date

2026-07-22

spl set id

de34bcb7-b524-45c8-9181-61c6f48d540e

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 9 · unclassified context

application numbers

BLA761086

brand names

AVSOLA

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1805
end exclusive: true
exact text: ination with methotrexate : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active disease. ( 1.5 ) Ankylosing Spondylitis : reducing signs and symptoms in adult patients with active disease. ( 1.6 ) Psoriatic Arthritis : reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients. ( 1.7 ) Plaque Psori
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 1306

current approval status

not_reconciled

duplicate text group

dup-56c7e48cfecd228e120e

extraction review status

automated_candidate_pending_source_review

generic names

INFLIXIMAB-AXXQ

ind-span-22ad196eddf868f32647

label id

dac3f1a8-101b-46cf-86b7-f289bc764813

positive predicate support span

Source null

qualifier mentions

context exact
5 ) Ankylosing Spondylitis : reducing signs and symptoms in adult patients with active disease.
kind
age
polarity
not_inferred
span
end
1584
end exclusive
true
exact text
adult patients
label id
dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start
1570

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1605
end exclusive: true
exact text: ( 1.5 ) Ankylosing Spondylitis : reducing signs and symptoms in adult patients with active disease.
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 1506

source url

https://api.fda.gov/drug/label.json?search=id%3A%22dac3f1a8-101b-46cf-86b7-f289bc764813%22

spl effective date

2026-07-22

spl set id

de34bcb7-b524-45c8-9181-61c6f48d540e

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 10 · unclassified context

application numbers

BLA761086

brand names

AVSOLA

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1984
end exclusive: true
exact text: mage, and improving physical function in adult patients with moderately to severely active disease. ( 1.5 ) Ankylosing Spondylitis : reducing signs and symptoms in adult patients with active disease. ( 1.6 ) Psoriatic Arthritis : reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients. ( 1.7 ) Plaque Psoriasis : treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapie
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 1406

current approval status

not_reconciled

duplicate text group

dup-aa018bfc49729953fe7e

extraction review status

automated_candidate_pending_source_review

generic names

INFLIXIMAB-AXXQ

ind-span-a46ce64636432fa8ac37

label id

dac3f1a8-101b-46cf-86b7-f289bc764813

positive predicate support span

Source null

qualifier mentions

context exact
on of structural damage, and improving physical function in adult patients.
kind
age
polarity
not_inferred
span
end
1783
end exclusive
true
exact text
adult patients
label id
dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start
1769

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1784
end exclusive: true
exact text: ( 1.6 ) Psoriatic Arthritis : reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients.
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 1606

source url

https://api.fda.gov/drug/label.json?search=id%3A%22dac3f1a8-101b-46cf-86b7-f289bc764813%22

spl effective date

2026-07-22

spl set id

de34bcb7-b524-45c8-9181-61c6f48d540e

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 11 · unclassified context

application numbers

BLA761086

brand names

AVSOLA

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2217
end exclusive: true
exact text: with active disease. ( 1.6 ) Psoriatic Arthritis : reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients. ( 1.7 ) Plaque Psoriasis : treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. ( 1.8 ) 1.1 Crohn's Disease AVSOLA is indicated for: reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease (
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 1585

current approval status

not_reconciled

duplicate text group

dup-f5337bf4af6eb05c961c

extraction review status

automated_candidate_pending_source_review

generic names

INFLIXIMAB-AXXQ

ind-span-f144d9a2037d60392cf0

label id

dac3f1a8-101b-46cf-86b7-f289bc764813

positive predicate support span

Source null

qualifier mentions

context exact
( 1.7 ) Plaque Psoriasis : treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaq
kind
age
polarity
not_inferred
span
end
1839
end exclusive
true
exact text
adult patients
label id
dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start
1825

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 2017
end exclusive: true
exact text: ( 1.7 ) Plaque Psoriasis : treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate.
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 1785

source url

https://api.fda.gov/drug/label.json?search=id%3A%22dac3f1a8-101b-46cf-86b7-f289bc764813%22

spl effective date

2026-07-22

spl set id

de34bcb7-b524-45c8-9181-61c6f48d540e

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 12 · unclassified context

application numbers

BLA761086

brand names

AVSOLA

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2225
end exclusive: true
exact text: ent of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. ( 1.8 ) 1.1 Crohn's Disease AVSOLA is indicated for: reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease (CD) who
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 1818

current approval status

not_reconciled

duplicate text group

dup-0baf12d3e30a2aed476d

extraction review status

automated_candidate_pending_source_review

generic names

INFLIXIMAB-AXXQ

ind-span-e2dea16572745d192821

label id

dac3f1a8-101b-46cf-86b7-f289bc764813

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 2025
end exclusive: true
exact text: ( 1.8 )
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 2018

source url

https://api.fda.gov/drug/label.json?search=id%3A%22dac3f1a8-101b-46cf-86b7-f289bc764813%22

spl effective date

2026-07-22

spl set id

de34bcb7-b524-45c8-9181-61c6f48d540e

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 13 · positive indication candidate

application numbers

BLA761086

brand names

AVSOLA

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2626
end exclusive: true
exact text: dult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. ( 1.8 ) 1.1 Crohn's Disease AVSOLA is indicated for: reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease (CD) who have had an inadequate response to conventional therapy. reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing CD. 1.2 Pediatric Crohn's Disease AVSOLA is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to sev
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 1826

current approval status

not_reconciled

duplicate text group

dup-4c6523c22359c7eac6e4

extraction review status

automated_candidate_pending_source_review

generic names

INFLIXIMAB-AXXQ

ind-span-8d4cad2590d4854deb3c

label id

dac3f1a8-101b-46cf-86b7-f289bc764813

positive predicate support span

end: 2065
end exclusive: true
exact text: is indicated
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 2053

qualifier mentions

context exact
symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease (CD) who
kind
age
polarity
not_inferred
span
end
2164
end exclusive
true
exact text
adult patients
label id
dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start
2150
context exact
nd rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing CD.
kind
age
polarity
not_inferred
span
end
2405
end exclusive
true
exact text
adult patients
label id
dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start
2391

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 2426
end exclusive: true
exact text: 1.1 Crohn's Disease AVSOLA is indicated for: reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease (CD) who have had an inadequate response to conventional therapy. reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing CD.
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 2026

source url

https://api.fda.gov/drug/label.json?search=id%3A%22dac3f1a8-101b-46cf-86b7-f289bc764813%22

spl effective date

2026-07-22

spl set id

de34bcb7-b524-45c8-9181-61c6f48d540e

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 14 · positive indication candidate

application numbers

BLA761086

brand names

AVSOLA

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2902
end exclusive: true
exact text: ve had an inadequate response to conventional therapy. reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing CD. 1.2 Pediatric Crohn's Disease AVSOLA is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active CD who have had an inadequate response to conventional therapy. 1.3 Ulcerative Colitis AVSOLA is indicated for reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 2227

current approval status

not_reconciled

duplicate text group

dup-edd13d15ce3787113fc8

extraction review status

automated_candidate_pending_source_review

generic names

INFLIXIMAB-AXXQ

ind-span-4183800bc88e9cca6cb9

label id

dac3f1a8-101b-46cf-86b7-f289bc764813

positive predicate support span

end: 2476
end exclusive: true
exact text: is indicated
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 2464

qualifier mentions

context exact
1.2 Pediatric Crohn's Disease AVSOLA is indicated for reducing signs and
kind
age
polarity
not_inferred
span
end
2440
end exclusive
true
exact text
Pediatric
label id
dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start
2431
context exact
symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active
kind
age
polarity
not_inferred
span
end
2578
end exclusive
true
exact text
pediatric patients
label id
dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start
2560
context exact
ng and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active CD who have ha
kind
age
polarity
not_inferred
span
end
2593
end exclusive
true
exact text
6 years of age
label id
dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start
2579

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 2702
end exclusive: true
exact text: 1.2 Pediatric Crohn's Disease AVSOLA is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active CD who have had an inadequate response to conventional therapy.
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 2427

source url

https://api.fda.gov/drug/label.json?search=id%3A%22dac3f1a8-101b-46cf-86b7-f289bc764813%22

spl effective date

2026-07-22

spl set id

de34bcb7-b524-45c8-9181-61c6f48d540e

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 15 · positive indication candidate

application numbers

BLA761086

brand names

AVSOLA

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 3216
end exclusive: true
exact text: ptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active CD who have had an inadequate response to conventional therapy. 1.3 Ulcerative Colitis AVSOLA is indicated for reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to conventional therapy. 1.4 Pediatric Ulcerative Colitis AVSOLA is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 2503

current approval status

not_reconciled

duplicate text group

dup-8e2cabf3b2ee4fe9ea91

extraction review status

automated_candidate_pending_source_review

generic names

INFLIXIMAB-AXXQ

ind-span-4b9cd4559650ea718d87

label id

dac3f1a8-101b-46cf-86b7-f289bc764813

positive predicate support span

end: 2745
end exclusive: true
exact text: is indicated
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 2733

qualifier mentions

context exact
and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active ulcerative colitis (UC)
kind
age
polarity
not_inferred
span
end
2896
end exclusive
true
exact text
adult patients
label id
dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start
2882

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 3016
end exclusive: true
exact text: 1.3 Ulcerative Colitis AVSOLA is indicated for reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to conventional therapy.
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 2703

source url

https://api.fda.gov/drug/label.json?search=id%3A%22dac3f1a8-101b-46cf-86b7-f289bc764813%22

spl effective date

2026-07-22

spl set id

de34bcb7-b524-45c8-9181-61c6f48d540e

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 16 · positive indication candidate

application numbers

BLA761086

brand names

AVSOLA

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 3495
end exclusive: true
exact text: ssion and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to conventional therapy. 1.4 Pediatric Ulcerative Colitis AVSOLA is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active UC who have had an inadequate response to conventional therapy. 1.5 Rheumatoid Arthritis AVSOLA, in combination with methotrexate, is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in ad
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 2817

current approval status

not_reconciled

duplicate text group

dup-e4259b1be1e7f5a73278

extraction review status

automated_candidate_pending_source_review

generic names

INFLIXIMAB-AXXQ

ind-span-66c840a2f480c060db95

label id

dac3f1a8-101b-46cf-86b7-f289bc764813

positive predicate support span

end: 3069
end exclusive: true
exact text: is indicated
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 3057

qualifier mentions

context exact
1.4 Pediatric Ulcerative Colitis AVSOLA is indicated for reducing signs a
kind
age
polarity
not_inferred
span
end
3030
end exclusive
true
exact text
Pediatric
label id
dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start
3021
context exact
symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active
kind
age
polarity
not_inferred
span
end
3171
end exclusive
true
exact text
pediatric patients
label id
dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start
3153
context exact
ng and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active UC who have ha
kind
age
polarity
not_inferred
span
end
3186
end exclusive
true
exact text
6 years of age
label id
dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start
3172

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 3295
end exclusive: true
exact text: 1.4 Pediatric Ulcerative Colitis AVSOLA is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active UC who have had an inadequate response to conventional therapy.
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 3017

source url

https://api.fda.gov/drug/label.json?search=id%3A%22dac3f1a8-101b-46cf-86b7-f289bc764813%22

spl effective date

2026-07-22

spl set id

de34bcb7-b524-45c8-9181-61c6f48d540e

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 17 · positive indication candidate

application numbers

BLA761086

brand names

AVSOLA

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 3769
end exclusive: true
exact text: ptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active UC who have had an inadequate response to conventional therapy. 1.5 Rheumatoid Arthritis AVSOLA, in combination with methotrexate, is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis (RA). 1.6 Ankylosing Spondylitis AVSOLA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis (AS). 1.7 Psoriatic Arthritis AVSOLA is indicated for reducing sign
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 3096

current approval status

not_reconciled

duplicate text group

dup-409008439af13f3ac971

extraction review status

automated_candidate_pending_source_review

generic names

INFLIXIMAB-AXXQ

ind-span-bb045b1f266b7f33a325

label id

dac3f1a8-101b-46cf-86b7-f289bc764813

positive predicate support span

end: 3375
end exclusive: true
exact text: is indicated
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 3363

qualifier mentions

context exact
on of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis (RA
kind
age
polarity
not_inferred
span
end
3507
end exclusive
true
exact text
adult patients
label id
dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start
3493
context exact
1.5 Rheumatoid Arthritis AVSOLA, in combination with methotrexate, is indicated for reducing signs and symptoms, inhibiting t
kind
biomarker
polarity
not_inferred
span
end
3361
end exclusive
true
exact text
methotrexate
label id
dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start
3349
context exact
1.5 Rheumatoid Arthritis AVSOLA, in combination with methotrexate, is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis (RA)
kind
regimen
polarity
not_inferred
span
end
3508
end exclusive
true
exact text
in combination with methotrexate, is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients
label id
dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start
3329

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 3569
end exclusive: true
exact text: 1.5 Rheumatoid Arthritis AVSOLA, in combination with methotrexate, is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis (RA).
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 3296

source url

https://api.fda.gov/drug/label.json?search=id%3A%22dac3f1a8-101b-46cf-86b7-f289bc764813%22

spl effective date

2026-07-22

spl set id

de34bcb7-b524-45c8-9181-61c6f48d540e

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 18 · positive indication candidate

application numbers

BLA761086

brand names

AVSOLA

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 3907
end exclusive: true
exact text: cated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis (RA). 1.6 Ankylosing Spondylitis AVSOLA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis (AS). 1.7 Psoriatic Arthritis AVSOLA is indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients wit
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 3370

current approval status

not_reconciled

duplicate text group

dup-8bdc6f95585ea1d157d3

extraction review status

automated_candidate_pending_source_review

generic names

INFLIXIMAB-AXXQ

ind-span-8ef68199c4b75413d04d

label id

dac3f1a8-101b-46cf-86b7-f289bc764813

positive predicate support span

end: 3616
end exclusive: true
exact text: is indicated
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 3604

qualifier mentions

context exact
itis AVSOLA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis (AS).
kind
age
polarity
not_inferred
span
end
3666
end exclusive
true
exact text
adult patients
label id
dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start
3652

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 3707
end exclusive: true
exact text: 1.6 Ankylosing Spondylitis AVSOLA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis (AS).
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 3570

source url

https://api.fda.gov/drug/label.json?search=id%3A%22dac3f1a8-101b-46cf-86b7-f289bc764813%22

spl effective date

2026-07-22

spl set id

de34bcb7-b524-45c8-9181-61c6f48d540e

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 19 · positive indication candidate

application numbers

BLA761086

brand names

AVSOLA

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 4135
end exclusive: true
exact text: with moderately to severely active rheumatoid arthritis (RA). 1.6 Ankylosing Spondylitis AVSOLA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis (AS). 1.7 Psoriatic Arthritis AVSOLA is indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients with psoriatic arthritis (PsA). 1.8 Plaque Psoriasis AVSOLA is indicated for the treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis (Ps) who are candidates for systemic therapy and w
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 3508

current approval status

not_reconciled

duplicate text group

dup-0ea23b5b97e7ad7538b9

extraction review status

automated_candidate_pending_source_review

generic names

INFLIXIMAB-AXXQ

ind-span-ad14b14bb53d557d4151

label id

dac3f1a8-101b-46cf-86b7-f289bc764813

positive predicate support span

end: 3751
end exclusive: true
exact text: is indicated
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 3739

qualifier mentions

context exact
on of structural damage, and improving physical function in adult patients with psoriatic arthritis (PsA).
kind
age
polarity
not_inferred
span
end
3903
end exclusive
true
exact text
adult patients
label id
dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start
3889

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 3935
end exclusive: true
exact text: 1.7 Psoriatic Arthritis AVSOLA is indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients with psoriatic arthritis (PsA).
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 3708

source url

https://api.fda.gov/drug/label.json?search=id%3A%22dac3f1a8-101b-46cf-86b7-f289bc764813%22

spl effective date

2026-07-22

spl set id

de34bcb7-b524-45c8-9181-61c6f48d540e

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 20 · positive indication candidate

application numbers

BLA761086

brand names

AVSOLA

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 4379
end exclusive: true
exact text: LA is indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients with psoriatic arthritis (PsA). 1.8 Plaque Psoriasis AVSOLA is indicated for the treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis (Ps) who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. AVSOLA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Boxed Warning and Warnings and Precautions (5) ] .
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 3736

current approval status

not_reconciled

duplicate text group

dup-db9d861a22517d913ee8

extraction review status

automated_candidate_pending_source_review

generic names

INFLIXIMAB-AXXQ

ind-span-bf0e17dae0356195a4a6

label id

dac3f1a8-101b-46cf-86b7-f289bc764813

positive predicate support span

end: 3976
end exclusive: true
exact text: is indicated
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 3964

qualifier mentions

context exact
8 Plaque Psoriasis AVSOLA is indicated for the treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaq
kind
age
polarity
not_inferred
span
end
4012
end exclusive
true
exact text
adult patients
label id
dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start
3998

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 4195
end exclusive: true
exact text: 1.8 Plaque Psoriasis AVSOLA is indicated for the treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis (Ps) who are candidates for systemic therapy and when other systemic therapies are medically less appropriate.
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 3936

source url

https://api.fda.gov/drug/label.json?search=id%3A%22dac3f1a8-101b-46cf-86b7-f289bc764813%22

spl effective date

2026-07-22

spl set id

de34bcb7-b524-45c8-9181-61c6f48d540e

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 21 · risk or warning

application numbers

BLA761086

brand names

AVSOLA

classification reasons

risk_or_warning_words_without_positive_predicate

clinical review status

pending

content role

risk_or_warning

context span

end: 4379
end exclusive: true
exact text: f adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis (Ps) who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. AVSOLA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Boxed Warning and Warnings and Precautions (5) ] .
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 3996

current approval status

not_reconciled

duplicate text group

dup-6b7476cdedb2c4ad2503

extraction review status

automated_candidate_pending_source_review

generic names

INFLIXIMAB-AXXQ

ind-span-12f5b02e007b3e59bb24

label id

dac3f1a8-101b-46cf-86b7-f289bc764813

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 4379
end exclusive: true
exact text: AVSOLA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Boxed Warning and Warnings and Precautions (5) ] .
label id: dac3f1a8-101b-46cf-86b7-f289bc764813
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: bc06c1f2030134744a64deae8f56bde440bbe5767b3375da4e1f9d735bddbf33
start: 4196

source url

https://api.fda.gov/drug/label.json?search=id%3A%22dac3f1a8-101b-46cf-86b7-f289bc764813%22

spl effective date

2026-07-22

spl set id

de34bcb7-b524-45c8-9181-61c6f48d540e

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Preserved source evidence · Not medical advice